A Clinical Manifesto on SGLT2 Inhibitors in Patients With Heart Failure
Published: 25 August 2020
-
Views:
26
-
Likes:
7
-
Views:
26
-
Likes:
7
-
Up Next
-
1m 13sPart 1 Welcome & Introductions Martin R Cowie
-
23m 30sPart 2 Health: SGLT2 Inhibitors and Quality of Life Shelley Zieroth, Martin R Cowie
-
25m 15sPart 3 Protect: SGLT2 Inhibitors in Patients with HF Nikolaus Marx, Martin R Cowie
-
20m 8sPart 4 Wealth: An Abundance (and More to Come) of SGLT2 Inhibitor Evidence Stefan Anker, Andrew JS Coats
Overview
This educational symposium was part of the eSPACE Heart Failure meeting held 11-14 July 2020.
The session focuses on latest data and practical implication of SGLT2 Inhibitors in Heart Failure patients.
Learning objectives
- Encourage conversation around SGLT2 inhibitors as cardiovascular therapies with cardio–renal benefits
- Highlight and discuss profiles of appropriate patients for initiation of an SGLT2 inhibitor, and share with cardiologists the well-established safety profile of and the clinical considerations for treatment with an SGLT2 inhibitor
- Inform cardiologists of the current evidence and ongoing trials for SGLT2 inhibitors in patients with heart failure
Symposium Agenda
Time - Session title and objective - Speaker(s)
- 25 mins - Health: SGLT2 inhibitors and quality of life - Martin Cowie, Shelley Zieroth
- 5 mins - Transition
- 25 mins - Protect: SGLT2 inhibitors in patients with HF - Martin Cowie, Nikolaus Marx
- 5 mins - Transition
- 25 mins - Wealth: An abundance (and more to come) of SGLT2 inhibitor evidence - Stefan Anker, Andrew Coats
- 5 mins - Close
More from this programme
Part 1
Welcome & Introductions
| 1 session | |
| Welcome & Introductions | Watch now |
Part 2
Health: SGLT2 Inhibitors and Quality of Life
Part 3
Protect: SGLT2 Inhibitors in Patients with HF
Part 4
Wealth: An Abundance (and More to Come) of SGLT2 Inhibitor Evidence
Part 5
Panel Discussion
| 1 session | |
| Panel Discussion | Watch now |
Faculty Biographies
Andrew JS Coats
Director of the Monash Warwick Alliance and Academic Vice-President
Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.
Prof Coats attended Melbourne Grammar School and studied at Oxford and Cambridge. He has a higher doctorates from Oxford (DM) and Imperial (DSc.).
Prof Coats was appointed Viscount Royston Professor of Cardiology at Imperial College in 1996 and Director of Cardiology and Associate Medical Director of the Royal Brompton and Harefield NHS trust. Professor Coats was appointed Dean of Medicine at the University of Sydney in 2002, and subsequently Deputy Vice-Chancellor. Professor Coats was most recently CEO of the Norwich Research Park, the UK's oldest and largest research and innovation park.
Prof Coats research interests are chronic heart failure, hypertension, and organizational…
Stefan Anker
Professor of Cardiology
Dr Stefan D Anker, Professor of Cardiology and Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany, and served as the 2012–14 President of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).